Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Beltran-Bless, AA; Clemons, MJ; Fesl, C; Greil, R; Pond, GR; Balic, M; Vandermeer, L; Bjelic-Radisic, V; Singer, CF; Steger, GG; Helfgott, R; Egle, D; Solkner, L; Gampenrieder, SP; Kacerovsky-Strobl, S; Suppan, C; Ritter, M; Rinnerthaler, G; Pfeiler, G; Fohler, H; Hlauschek, D; Hilton, J; Gnant, M.
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12
EUR J CANCER. 2023; 180: 108-116. Doi: 10.1016/j.ejca.2022.12.003
Web of Science PubMed FullText FullText_MUG


Co-authors Med Uni Graz
Balic Marija
Bjelic-Radisic Vesna
Suppan Christoph

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Background: The widespread adoption of adjuvant bisphosphonate therapy for postmenopausal early breast cancer (EBC) patients was based on results of the Early Breast Cancer Trialist Group (EBCTCG) meta-analysis. Despite multiple regimens evaluated, there was no signal of varying efficacy with type, dose/dose intensity of bisphosphonate administra-tion. We evaluated the effect of early treatment cessation using long-term outcome data from the ABCSG-12 trial.Patients and methods: ABCSG-12 randomized 1803 hormone-receptor positive EBC patients on ovarian suppression between 1999 and 2006 to receive 4 mg zoledronic acid 6-monthly or not (and tamoxifen or anastrozole, 2:2 factorial design). In the current study, we evaluated whether the number of zoledronate infusions had an impact on breast cancer-specific out-comes. We hypothesized that amongst patients who received at least one zoledronate infusion, the number of infusions had no effect on outcomes. Time-to-event endpoints were analysed with Cox models and Kaplan Meier curves starting from a 3-year landmark. BMD analysis was restricted to patients who participated in the BMD sub-study.Results: 725 patients who received at least one zoledronate infusion were included in the time -to-event analysis. There was no statistically significant difference in disease-free or overall sur-vival in the patients who received <6 zoledronate infusions (n = 170) compared to those who received >7 zoledronate infusions (n = 555). Conclusions: Comparable to efforts to de-escalate treatment duration in metastatic bone dis-ease, there was no evidence to indicate that a reduced number of zoledronate infusions is asso-ciated with reduced adjuvant efficacy. Further studies to define optimal regimens of adjuvant bone-targeted therapies are required. Crown Copyright 2022 Published by Elsevier Ltd. All rights reserved.

Find related publications in this database (Keywords)
Breast cancer
Adjuvant bisphosphonate
© Med Uni GrazImprint